Benzodiazepines (Psy and mixed indications) updated on 02-10-2025

Craniosynostosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15464
R63606		 Blotière - Clonazepam (Other indications), 2019 Craniosynostosis 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.25 [0.08;20.00] C 0/980   766/1,875,733 766 980
ref
S15593
R64235		 Tinker - BZDs, 2019 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 0.60 [0.30;1.10] 9/90   1,570/13,022 1,579 90
ref
Total 2 studies 0.62 [0.33;1.17] 2,345 1,070
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière - Clonazepam (Other indications), 2019Blotière - Clonazepam, 2019 1 1.25[0.08; 20.00]7669805%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker - BZDs, 2019Tinker - BZDs, 2019 0.60[0.30; 1.10]1,5799095%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 0% 0.62[0.33; 1.17]2,3451,0700.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Other indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.25[0.08; 20.00]766980 -NABlotière - Clonazepam (Other indications), 2019 1 case control studiescase control studies 0.60[0.31; 1.15]1,57990 -NATinker - BZDs, 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.62[0.33; 1.17]2,3451,0700%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 2 Tags Adjustment   - No  - No 1.25[0.08; 20.00]766980 -NABlotière - Clonazepam (Other indications), 2019 1   - Yes  - Yes 0.60[0.31; 1.15]1,57990 -NATinker - BZDs, 2019 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.25[0.08; 20.00]766980 -NABlotière - Clonazepam (Other indications), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 0.60[0.31; 1.15]1,57990 -NATinker - BZDs, 2019 1 All studiesAll studies 0.62[0.33; 1.17]2,3451,0700%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.62[0.33; 1.17]2,3451,0700%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 20.510.01.0